Articles tagged with Multiple Myeloma
Australian researchers have discovered a new class of anti-cancer agents targeting MCL-1, which may be effective in treating multiple myeloma. The majority of myelomas rely on MCL-1 to stay alive, and inhibiting it has shown potential as a treatment approach for the majority of patients.
Research shows that as body mass index increases, so does the growth and spread of multiple myeloma. Fat cells from obese or morbidly obese patients secrete inflammatory proteins that contribute to tumor progression. This study suggests a new treatment approach, tailoring drugs based on a patient's BMI.
A research team has identified the AF1q protein as an adverse prognostic factor for multiple myeloma, particularly in cases where extramedullary disease is present. The study found that high expression of AF1q is associated with a higher incidence of EMD.
Preliminary results suggest that the selinexor combination regimen is active in relapsed and refractory multiple myeloma. Of 10 evaluable patients, two each achieved a very good partial response, a partial response, and a minimal response.
A Phase I study of plitidepsin in combination with bortezomib and dexamethasone demonstrated a 56% overall response rate, including very good partial responses. The treatment was well-tolerated, with no dose-limiting toxicities, and showed clinical benefit in 72% of patients.
Researchers at Sylvester Comprehensive Cancer Center have developed an animal model of multiple myeloma, allowing them to better understand its mechanisms and test potential treatments. The study has the potential to improve outcomes for patients with this incurable disease.
Researchers discovered TJP1's role in identifying patients most likely to benefit from proteasome inhibitors, with low TJP1 levels associated with resistance. The study provides a rationale for using TJP1 as a biomarker for personalized treatment approaches.
Researchers have discovered that PPP3CA and calcineurin are potential therapeutic targets for treating multiple myeloma. The study found that inhibition of calcineurin with FK506 promoted MM cell death, suggesting a promising new approach for treating this disease.
A preliminary clinical trial found that an experimental antibody treatment decreased the number of cancer stem cells driving tumor growth in nearly all patients with multiple myeloma. The treatment was tested in 15 newly diagnosed patients and showed promising results, with no serious adverse side effects.
PharmaMar's Aplidin (plitidepsin) demonstrates a statistically significant reduction in multiple myeloma progression or death, meeting primary endpoint. The study enrolled 255 patients across 19 countries and showed promising results.
A new therapeutic approach using autograft followed by allograft resulted in a record-breaking 41% cure rate and 60% relapse-free survival rate in patients with multiple myeloma. The study showed promising results with low mortality rates and high efficacy in subsequent treatments.
A landmark Phase II study by Winship Cancer Institute led to the approval of daratumumab for multiple myeloma patients who have received at least three prior treatments. The drug showed an overall response rate of nearly 30% and demonstrated single-agent activity in a novel monoclonal antibody treatment.
Researchers presented landmark studies on newly diagnosed multiple myeloma, revealing key biological processes and disease mechanisms. Two combination therapy strategies showed high response rates in patients with difficult-to-treat myeloma.
A Phase I study combining natural killer cells with high-dose chemotherapy and stem cell transplantation showed promising results in treating multiple myeloma. The treatment resulted in no toxicity or graft-versus-host disease, offering a potential new approach for patients.
A new personalized method for testing drug effectiveness in multiple myeloma predicts the best treatments for individual patients. The test suggests commonly prescribed drugs or combination therapies, as well as optimal dosages.
Rates of kidney failure caused by multiple myeloma have declined over the past decade, with a 20% reduction from 2001-2002 to 2009-2010. ESRD patients with multiple myeloma are also living longer and experiencing a decline in mortality within 3 years after initiating dialysis.
A study of 100 multiple myeloma patients found that nearly half tapped into their savings and 17% delayed treatment due to high costs. The rising cost of novel therapeutics has led to financial toxicity, affecting patient wellbeing and potentially contributing to increased mortality.
A study published in JAMA Oncology found that Vietnam veterans exposed to Agent Orange have a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. The study suggests an association between Agent Orange exposure and the development of plasma cell disorders.
The Mayo Clinic Cancer Center has been awarded a Specialized Program of Research Excellence (SPORE) grant to study the genetic basis of multiple myeloma and develop novel therapies.
Daratumumab, a monoclonal antibody targeting CD38, showed significant promise against difficult-to-treat disease in patients with advanced multiple myeloma, achieving durable responses in 36% of patients, including complete remissions and very good partial responses.
Patients with multiple myeloma who are diagnosed with MGUS first have better overall survival compared to those without prior knowledge. However, the study also found that patients with low M-protein concentration at MGUS diagnosis have poorer MM survival rates.
A comprehensive review published in The Lancet provides guidance on treating multiple myeloma, including established and novel therapies. New approaches to paralyze cancer cells and attack malignant cells are also introduced.
Researchers found a significant benefit in adding carfilzomib to standard lenalidomide and dexamethasone treatment, extending disease-free periods by nearly 50%. The three-drug combination resulted in improved remission rates and overall survival, with patients reporting better quality of life.
Researchers present new advances in treating relapsed and treatment-resistant lymphoma, including targeted therapies and stem cell transplantation, to improve patient outcomes. These studies show promising results for patients with HIV-associated lymphoma, where traditional treatments have been limited.
The Multiple Myeloma Research Foundation has made landmark genomic and clinical data from the CoMMpass Study available to researchers via the MMRF's Researcher Gateway. This data includes patient-level biomarker and clinical data, genomic information, and treatment responses, offering new avenues for research into multiple myeloma.
A phase 1/2 study found the combination of weekly ixazomib plus lenalidomide and dexamethasone to be generally well-tolerated and active in patients with newly diagnosed multiple myeloma, resulting in a partial response rate of 92%. The study supports the development of a phase 3 trial for this combination.
The International Myeloma Working Group has updated its criteria for diagnosing multiple myeloma, allowing for earlier diagnosis without symptoms. The new guidelines incorporate validated biomarkers to identify patients at risk of progression, enabling targeted therapy and improved patient outcomes.
Scientists from A*STAR's Bioprocessing Technology Institute uncover crucial role of DOK3 and SHP1 in plasma cell development and production. This discovery advances understanding of plasma cells and antibody response, potentially leading to improved treatment for patients with autoimmune diseases like lupus and multiple myeloma.
Researchers at Ohio State University have developed a novel strategy for treating multiple myeloma by genetically modifying T lymphocytes to target the CS1 molecule on myeloma cells. The modified cells were shown to efficiently destroy human multiple myeloma cells in laboratory studies and animal models.
Researchers at VCU Massey Cancer Center have developed a novel combination therapy that reduces Mcl-1 expression and disrupts its interactions to effectively kill multiple myeloma cells. The therapy combines Chk1 and MEK inhibitors, showing promise in overcoming resistance caused by high expressions of Mcl-1.
A Mayo Clinic study found that blacks are twice as likely to develop multiple myeloma because they are more likely to have monoclonal gammopathy of undetermined significance (MGUS). The study also showed that the type of MGUS in blacks is associated with a higher risk of progression to full-blown multiple myeloma.
A pre-clinical study suggests that dinaciclib, a CDK inhibitor, can improve the effectiveness of certain therapies for multiple myeloma and myeloid leukemia by disrupting the unfolded protein response (UPR) in cancer cells. The UPR is a cell survival mechanism that allows cancer cells to combat damage caused by anti-cancer agents.
A comprehensive genetic study of multiple myeloma has identified subpopulations of cancer cells with different mutations within the same tumor. This discovery could impact treatment strategies and patient outcomes.
A research team identified two genes, IRE1 and XBP1, that control response to proteasome inhibitors, which are commonly used to treat multiple myeloma. The study found that these underlying progenitor cells can survive treatment and lead to disease relapse.
Multiple myeloma patients experience persistent disease recurrence due to intrinsic resistance in immature progenitor cells. Researchers identify a cancer cell maturation hierarchy and propose targeting both progenitor cells and plasma cells to develop new treatments.
Pomalidomide shows promise in treating CNS lymphoma by improving survival and suppressing tumor growth. The clinical trial is now open at Mayo Clinic's three campuses.
A new study led by Robert G. Hawley may help predict which patients with multiple myeloma will respond better to certain treatments. The researchers discovered a test that can detect tumor-propagating cells, which are responsible for disease relapse.
A large European study found that multiple myeloma is related to farm work, printing and cleaning. The EPILYMPH study, which included 277 cases and matched controls by age and gender, found an increased risk for farmers, cleaning workers, telephone and radio operators.
Pomalidomide, a new immunomodulatory drug, demonstrates significant increases in progression-free survival and overall survival for patients with relapsed and treatment-resistant multiple myeloma. The study found improved outcomes in both younger and older patients, offering a promising new option to extend survival.
A Phase II clinical trial led by Amir Toor shows promise in providing lasting protection against multiple myeloma progression after a stem cell transplant. The therapy forces cancer cells to express proteins that immune system cells can recognize as foreign, boosting the production of T-cell lymphocytes.
Researchers at VCU Massey Cancer Center have developed a new combination therapy that dramatically increases multiple myeloma cell death. The treatment, involving obatoclax and flavopiridol, promotes apoptosis through different mechanisms, offering new hope for patients with multiple myeloma.
Researchers at John Theurer Cancer Center found carfilzomib to be clinically significant in responding heavily-pretreated patients with relapsed and refractory multiple myeloma. In the multi-center phase IIb study, ORR was 23.7% with median DOR of 7.8 months.
A novel gene variant associated with reduced cholesterol levels has been identified in human populations. Additionally, a new approach for treating Parkinson's disease using embryonic stem cell therapy is proposed. Furthermore, research suggests that brain indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in the concurrence of ...
A new frontline treatment regimen combining carfilzomib, lenalidomide, and low-dose dexamethasone resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. The study found that the regimen was well-tolerated, with improved responses as treatment continued.
A three-drug treatment combining carfilzomib, lenalidomide, and low-dose dexamethasone showed rapid and durable responses in newly diagnosed multiple myeloma patients. After at least eight cycles of treatment, 61% had a stringent complete response.
Scientists at NYU School of Medicine identified a pathway that, if deactivated, may help slow the development of multiple myeloma. By targeting this pathway's cellular transcription process, researchers hope to find an effective treatment for the disease.
A new maintenance therapy, lenalidomide, has been shown to improve outcomes for patients with newly diagnosed multiple myeloma who have undergone a stem cell transplant. The study found that patients treated with lenalidomide had a 59% chance of surviving free of disease progression after three years.
The MMRF has partnered with TGen, Spectrum Health, and VARI to provide genomic services and analyze patient samples in a landmark 1000-patient study on multiple myeloma. The study aims to identify specific subgroups of patients and provide insights into the molecular changes that affect disease progression.
A recent study published in Journal of Oncology reveals that MAL3-101, a heat shock protein 70 inhibitor, exhibits potent anti-myeloma effects both in vitro and in vivo. The compound boosts the effectiveness of proteasome inhibitors like bortezomib when used synergistically.
A new study found a possible link between resistance to immunomodulator therapy and the presence of protein cereblon. Lowering cereblon levels allows IMiDs to work properly, suggesting that other mechanisms may play a role in drug resistance.
The John Theurer Cancer Center is participating in a landmark clinical trial to develop personalized treatments for patients with multiple myeloma. The study aims to accelerate translational research into therapeutic breakthroughs, leveraging genomic portraits and tissue sampling.
A phase 3 trial found subcutaneous administration of bortezomib to be as effective as intravenous delivery, but with a better safety profile and lower rates of peripheral neuropathy. Subcutaneous injection could provide an easy home-based treatment option at reduced cost.
A study of nearly 40 tumor genomes has yielded new and unexpected insights into the events that lead to multiple myeloma, a form of blood cancer. The researchers discovered genes never before associated with cancer, as well as genetic mutations disrupting common pathways that trigger cell change.
Researchers sequenced the genome of multiple myeloma in a landmark study, identifying mutations in genes involved in protein translation, blood coagulation, and histone methylation. The findings provide new insights into the disease's development and offer potential directions for targeted therapies.
Scientists at VCU Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The combination regimen of Src inhibitors and Chk1 inhibitors induces cell death in multiple myeloma cells while sparing healthy cells.
A new three-drug combination, CRd, has shown promising results in treating newly diagnosed blood cancer patients, including a high response rate and minimal side effects. The study found that all participants responded to treatment and achieved significant reductions in disease.
Researchers have identified key molecules in multiple myeloma that can trigger expression of the P53 tumor suppressor gene, slowing cell growth and leading to death. The study suggests re-activating these microRNAs could provide a new treatment strategy for the disease.
A study by Mayo Clinic and TGen reveals that DNA methylation is altered with increasing severity in multiple myeloma, leading to the overexpression of oncogenes. The researchers found hypomethylation at specific points of DNA, associated with myeloma development, and suggest it may have prognostic value.
A less intensive bortezomib-based regimen is as effective as the standard treatment for elderly patients with multiple myeloma, but with fewer serious side effects. The regimen resulted in a reduction in peripheral neuropathy and gastrointestinal symptoms while maintaining efficacy.
Researchers identify silencing genes in malignant plasma cells that can be targeted by inhibitors of the Polycomb repressor complex. This approach may lead to new strategies for treating multiple myeloma.